Coronavirus and IBD Reporting Registry!
News! (24.2.2022) The SECURE-IBD team has announced the close-down of reporting to the SECURE-IBD database. SECURE-IBD served
a valuable purpose at a time when our IBD community needed fast answers to pressing questions. As we move into a new phase of the pandemic with different variants, evolving vaccines and vaccination strategies, re-infections, and COVID-specific treatments, the most pressing questions have shifted away from “What are the medication and other risk factors for developing a more severe course of COVID-19 in patients with IBD?” to new questions about vaccines, immunity, testing, and treatments. As SECURE-IBD was designed to address the initial question rather than these current questions, we believe that new studies are needed and that continued reporting to SECURE-IBD will not be as valuable as earlier in the pandemic. Read closing letter for more information: SECURE-IBD_final newsletter.pdf
What was SECURE-IBD?
Surveillance Epidemiology of Coronavirus Under Research Exclusion (SECURE-IBD) is an international, pediatric and adult registry to monitor and report on outcomes of COVID-19 occurring in IBD patients.
As of December 8, 2020, there have been 3,561 COVID-19 cases in IBD patients reported in SECURE-IBD with an increasing number of countries reporting ≥50 cases. This uptrend is concerning and we hope that the vaccine signals light at the end of the tunnel. The SECURE'IBD team is pleased to announce the approval of two excellent applications for ancillary studies using de-identified SECUREIBD data. These include a study on COVID-19 outcomes in Latin America and another to determine the impact of IBD activity on COVID-19 outcomes.
For more information please go to: https://covidibd.org/